Home Featured

Featured

Latest

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

Numinus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy Training Program

Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

Psychedelics Weekly – More Trouble For Field Trip Health, Ketamine Wellness Centers Abruptly Close, & The Creation of the Psychedelic Medicine PAC

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Psyence Group Announces Cantheon Capital Private Placement

Field Trip Health & Wellness Obtains CCAA Protection

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted...

Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on...

PT400 – Beckley Retreats: Combining Modern Science, Tradition, and Holistic Wellness

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in...

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Algernon Pharmaceuticals Announces Launch of Rights Offering

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration...

12 3...203 Page 1 of 203

EDITOR PICKS

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual...

Numinus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy...

Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

Numinus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy Training Program

Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

Psychedelics Weekly – More Trouble For Field Trip Health, Ketamine Wellness Centers Abruptly Close, & The Creation of the Psychedelic Medicine PAC

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Psyence Group Announces Cantheon Capital Private Placement

Field Trip Health & Wellness Obtains CCAA Protection

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted...

Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on...

PT400 – Beckley Retreats: Combining Modern Science, Tradition, and Holistic Wellness

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in...

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Algernon Pharmaceuticals Announces Launch of Rights Offering

Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration...

EDITOR PICKS

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual...

Numinus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy...

Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

POPULAR CATEGORY